End-of-day quote Nasdaq 04:30:00 05/02/2024 am IST 5-day change 1st Jan Change
17.59 USD -.--% Intraday chart for CALYXTPAR +2.93% -10.44%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cibus, Inc.(NasdaqCM:CBUS) added to Russell Small Cap Comp Value Index CI
Cibus, Inc.(NasdaqCM:CBUS) added to Russell Small Cap Completeness Index CI
Cibus, Inc.(NasdaqCM:CBUS) added to Russell 3000 Value Index CI
Cibus, Inc.(NasdaqCM:CBUS) added to Russell 2000 Index CI
Cibus, Inc.(NasdaqCM:CBUS) added to Russell 3000E Index CI
Cibus, Inc.(NasdaqCM:CBUS) added to Russell Microcap Index CI
Cibus, Inc.(NasdaqCM:CBUS) added to Russell 2500 Value Index CI
Cibus, Inc.(NasdaqCM:CBUS) added to Russell 2000 Value Index CI
Cibus, Inc.(NasdaqCM:CBUS) added to Russell 2000 Dynamic Index CI
Cibus, Inc.(NasdaqCM:CBUS) added to Russell Microcap Value Index CI
Cibus, Inc.(NasdaqCM:CBUS) added to Russell 2500 Index CI
Cibus, Inc.(NasdaqCM:CBUS) added to Russell 3000 Index CI
Cibus, Inc.(NasdaqCM:CBUS) added to Russell 3000E Value Index CI
Cibus, Inc. Expands Its Intellectual Property Coverage for Plant Gene Editing and Traits CI
Cibus? White Mold (Sclerotinia) Resistance Trait Program Confirms Important Milestone for Next Generation Gene Edits in Canola CI
Cibus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Transcript : Cibus, Inc., Q1 2024 Earnings Call, May 09, 2024
Cibus, Inc. Appoints Jason Stokes as Chief Legal Officer, General Counsel and Corporate Secretary CI
Cibus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Cibus, Inc., Q4 2023 Earnings Call, Mar 21, 2024
Cibus, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Cibus, Inc. Provides Impairment Charges Guidance for the Year Ended December 31, 2023 CI
Cibus, Inc. and Loveland Products Inc. Collaborate to Develop and Sell Rice Traits in the US CI
Cibus Nordic Real Estate Raises EUR50 Million from Senior Notes Issue MT
Cibus 2023 Field Trial Results Move Developed Traits Closer to Product Sales CI
Chart CALYXTPAR
More charts
Cibus, Inc. is an agricultural technology company that uses gene editing technologies to develop plant traits in seeds. Its business is the development of plant traits that help address specific productivity or yield challenges in farming, such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate. It is also engaged in developing, certain alternative plant-based oils or bio-based fermentation products. Its technology is its gene editing platform called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits, four of which are applicable to multiple crops. These traits are PSR in Canola and HT1 and HT3 in rice. In addition, it also has two advanced traits for Sclerotinia resistance and another novel broadleaf HT trait, HT2.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
8.4 USD
Average target price
23 USD
Spread / Average Target
+173.81%
Consensus
  1. Stock Market
  2. Equities
  3. CLXT Stock
  4. News CALYXTPAR
  5. Earnings Flash (CBUS) CIBUS US LLC Reports Q2 Revenue $197,000